Abstract - European Medical Journal

Continue

Abstracts

Respiratory
1 Mins
14 Nov 2019

What Do Patients Want in an Asthma App?

Asthma is estimated to affect 300 million people worldwide,1 and the literature advocates the beneficial effect of self-management programmes…
Respiratory
1 Mins
14 Nov 2019

Lung and Eye Pathology Develop Concurrently in a Neonatal Supplemental Oxygen Model

Bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) are two severe disorders that arise…
Respiratory
1 Mins
14 Nov 2019

Obstructive Sleep Apnea and Objective Sleep Quality in Non-Dialysed Patients with Chronic Kidney Disease: An European Sleep Apnea Database (ESADA) Study

Short sleep duration and poor sleep quality have been reported in chronic kidney disease (CKD). Additionally, sleep disordered breathing (SDB)…
Respiratory
1 Mins
14 Nov 2019

Changes in Biomarkers in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib and Sildenafil

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). Sildenafil is a phosphodiesterase-5…
Respiratory
2 Mins
14 Nov 2019

A Respiratory Review of Australian Men with Coal Mine Dust Lung Disease

In Queensland, Australia, coal mining is a large industry in terms of both employment and economy…
Respiratory
1 Mins
14 Nov 2019

Retrospective Validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort

Latest guidelines in pulmonary arterial hypertension (PAH) recommend the use of multi-parameter risk assessment at both diagnosis…
Oncology
1 Mins
12 Nov 2019

A Novel Affinity-Enhanced NY-ESO-1-Targeting TCR-Redirected T cell Transfer Exhibiting Early-Onset Cytokine Release Syndrome and Subsequent Tumour Responses in Synovial Sarcoma Patients

Adoptive transfer of T cell receptor (TCR)-redirected T cells has been reported to exhibit efficacy in some patients with melanoma and sarcoma…
Oncology
2 Mins
12 Nov 2019

A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Nonresectable or Metastatic Soft Tissue Sarcomas Who are Not Candidates for Chemotherapy

Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis with a median survival of 12–14 months.1 First-line therapy consists…